Reviews/Adhd Pharmacotherapy/Atomoxetine effective non-stimulant option for attention-deficit/hyperactivity disorder
Non Stimulant · ADHD-NONSTIM-01 · v2
The evidence shows atomoxetine reliably reduces core ADHD symptoms compared with a dummy pill in both adults and children, and works about as well as stimulants when the two are compared directly. The size of its benefit is genuinely moderate, but the numbers are not uniform: the cleanest placebo-controlled adult figure sits at the very bottom of the stated 0.5-0.7 range, while several other figures in children and in children with autism run higher. The panel accepted the core efficacy point and the rough magnitude, but noted that much of the supporting evidence is open-label comparisons against stimulants rather than clean placebo measurements. Critically, no study in this evidence set enrolls patients with substance-misuse risk or reasons they cannot take stimulants, so the claim's suitability-for-those-patients part has no backing here. Because the claim bundles a well-supported efficacy statement with an entirely unsupported suitability statement, the panel held it back rather than fully endorsing it.
Placebo-controlled trial data establish that atomoxetine improves ADHD symptoms versus placebo in adults ([1], [8]) and in children ([4], [6]), with a pooled 26-week adult effect size of 0.52 [1] and a placebo-controlled reduction of -14.3 versus -8.8 on CAARS in Asian adults [8]. Head-to-head randomized trials show it is efficacious and broadly comparable to methylphenidate in adults [2] and children ([3], [9]) and to methylphenidate adjunctive to SSRIs in comorbid depression [7]. Reported effect sizes cluster around and above the stated band: 0.51-0.88 on inattention in children [3] and 0.57-0.98 versus placebo in children with autism [6]. No paper in the corpus enrolls a substance-misuse or stimulant-contraindicated population. The contested point: The evidence divides on whether the tidy 0.5-0.7 band reflects the corpus: the only clean placebo-controlled figure is 0.52 [1], at the band's floor, while within-group and comorbid-population figures run to 0.88 [3] and 0.98 [6]. It also divides on evidence quality, since much of the 'effective' support is open-label active-comparator non-inferiority ([2], [3], [9]) rather than placebo-anchored, and [5] found atomoxetine inferior to lisdexamfetamine on total functional score.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Adhd Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The clause 'suitable for patients with stimulant contraindications or substance misuse risk' has no supporting paper in the corpus; no study enrolls a substance-misuse or stimulant-contraindicated population. This is claim overreach beyond the evidence.
The only clean placebo-controlled effect size (0.52, [1]) sits at the very floor of the claimed '0.5-0.7' band, while other cited figures ([3] up to 0.88, [6] up to 0.98) exceed it, so the tidy band is a selective summary rather than a uniform corpus finding.
Where it remains uncertain. The stated 0.5-0.7 band rests on a single placebo-controlled figure at its floor (0.52, [1]) while other figures exceed it ([3] to 0.88, [6] to 0.98), and no paper addresses substance-misuse or stimulant-contraindicated patients.
Aleatory
Several head-to-head trials are small (N=63 [2], N=60 [7], N=95 [9]), so individual effect estimates carry wide random variation.
Epistemic
No corpus study enrolls patients with substance-misuse risk or stimulant contraindications, so the suitability claim is untested here [1]-[9].
Inferential
Higher effect sizes come from an ASD-comorbid trial (0.57-0.98, [6]) and a comorbid-MDD trial [7], so extending them to general ADHD is an inference.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Placebo-controlled effect size of 0.52 anchors both the efficacy and the modest effect-size magnitude clause.
“By 26 weeks, mean change was -15.42 versus -9.71 (0.52 effect size). Atomoxetine treatment in adults with ADHD was associated with small effect sizes after 4 weeks and moderate effect sizes by 6 months of treatment.”
Panel auditInternal validity: high · scope of inference: Adults with ADHD treated up to 26 weeks; efficacy magnitude versus placebo.Key limitations: effect size only reaches 0.52 (lower end of claimed band) · no substance-misuse or contraindicated population · pooled post-hoc analysis
Head-to-head non-inferiority to a stimulant supports 'effective alternative'.
“Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD.”
Panel auditInternal validity: medium · scope of inference: Ethnic Chinese adults with ADHD; relative efficacy versus IR-methylphenidate.Key limitations: open-label · small n · no placebo control · no effect size reported
Pediatric effect sizes span and exceed the claimed 0.5-0.7 band.
“with effect sizes ranging from 0.51 to 0.88 on the Inattention subscale and from 0.29 to 0.57 on the Hyperactivity/Impulsivity subscale for atomoxetine”
Panel auditInternal validity: medium · scope of inference: Drug-naive children and adolescents 7-16 years; effect-size magnitude versus stimulant.Key limitations: open-label · no placebo control · hyperactivity effect sizes fall below the claimed band
Atomoxetine improved WFIRS-P scores from baseline in all domains, supporting effectiveness, although it was statistically inferior to the stimulant in total score and two domains.
Panel auditInternal validity: high · scope of inference: Children and adolescents 6-17 years with inadequate methylphenidate response; functional impairment versus lisdexamfetamine.Key limitations: atomoxetine statistically inferior to the stimulant · no placebo arm · no effect size in the claim's metric · sample size not stated in abstract
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus solidly carries efficacy and roughly the stated effect-size band but provides zero evidence for the substance-misuse suitability clause, holding the compound claim to Uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Substance-misuse population trial. The claim asserts suitability for substance-misuse-risk patients, but no corpus study enrolls them, so this limb is wholly unevidenced here. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo- or stimulant-controlled RCT of atomoxetine in ADHD patients with comorbid substance-use disorder, reporting symptom and misuse outcomes.
Open question: Is atomoxetine effective and safe in ADHD patients with comorbid substance-misuse risk? Why it is still open: No corpus paper enrolls a substance-misuse population, so the suitability clause has zero primary evidence here.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19